Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma

RNA Therapies Can Address the Unmet Needs That Are Prevalent In Chronic Disease Conditions

Online PR News – 02-February-2010 – – RNA therapies are the new class of biologic therapies developed to address severe unmet needs that are prevalent in chronic disease conditions such as oncology, autoimmune diseases and Central Nervous System (CNS) disorders. The majority of the current therapies approved for these indications either treat the symptoms of the disease or retard the rate at which the disease is progressing. Moreover, conventional therapies are associated with severe side effects such as bone marrow suppression, low platelet counts, sores in the mouth or throat, and nausea and vomiting. RNA therapies have the potential to address these unmet needs.
The prime causative factor for chronic diseases such as oncology and autoimmune diseases is protein overexpression. For example, researchers have studied that synovial tissue in patients with severe chronic rheumatoid arthritis has mutated p53 transcripts. Similarly, metastasis of breast and ovarian cancer is associated with overexpression of AKT2 protein kinase. Therefore, any therapy that can reduce overexpression of these disease-causing proteins will eventually address the potential unmet needs. RNA therapies are the ideal agents that can directly act on the biosynthesis process of these proteins and block their production.

For more information, please click or add the below link to your browser: http://www.globalmarketsdirect.com/Report.aspx?ID=Ribonucleic-Acid-(RNA)-Therapeutics-Strong-Potential-to-Address-Unmet-Needs-in-Pharma&Companyid=gbiresearch

Major pharmaceutical and biotechnology companies are attracted to the RNA therapeutics market and they are developing either internal research teams or partnering/acquiring external research units to build capabilities in this potential sector. Roche has set up its own R&D center in Kulmbach, Germany, for research on RNA therapies. Other large pharmaceutical and biotechnology firms such as Merck & Co have acquired RNA therapy-developing companies such as Sirna Therapeutics by paying huge amounts of money. Other companies are also adopting a strategic move into RNA therapeutics market by signing up deals with companies developing RNA therapies. In 2008-2009, the value of the total R&D licensing agreements involving RNA therapies was estimated at $3.7 billion. Furthermore, potential funding by venturing capitalists has also driven innovation in RNA therapeutics. Between 2003 and 2008, venture capitalists funded approximately $500 million on small and medium biotechnology companies developing RNA therapies. Major venture capitalists funding RNA therapies developing companies are Oxford Bioscience Partners, Skyline Ventures, LSP and Abingworth, Lilly Ventures, MedSciences Capital, Gimv (Antwerp) and HBM BioVentures Ltd.

For more information, please click or add the below link to your browser: http://www.globalmarketsdirect.com/Report.aspx?ID=Ribonucleic-Acid-(RNA)-Therapeutics-Strong-Potential-to-Address-Unmet-Needs-in-Pharma&Companyid=gbiresearch

GBI Research, the leading business intelligence provider, has released its latest research “Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma”, which provides insights into the unmet needs in the pharmaceutical market and potential segments where RNA therapies can prove to be useful. The report also delves deep into the market potential that RNA therapies hold in the future. Further, it provides insights into the R&D pipeline and the promising drugs. The study elucidates the current competitive landscape of the RNA therapeutics market. Finally, the report deals with key trend analysis on mergers and acquisitions, and licensing agreements involving RNA therapies. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

For more information, please click or add the below link to your browser: http://www.globalmarketsdirect.com/Report.aspx?ID=Ribonucleic-Acid-(RNA)-Therapeutics-Strong-Potential-to-Address-Unmet-Needs-in-Pharma&Companyid=gbiresearch

Or visit our report store: http://www.globalbusinessintelligence.com

Bookmarkse-mailGoogledel.icio.usStumbleUponSlashdotFurlDiggTechnoratiYahooMyWebBlinkListSpurlRawSugarWists
 
 
Contact Information
Rajesh Gunnam
Progressive House, Maidstone Road, Foots Cray, Sidcup
Kent London, DA14 5HZ

+914066166782